John C. Aplin

John C. Aplin, Ph.D. has served as a member of our board of directors since May 2003 and was recently appointed as Chairman. Since November 1990, Dr. Aplin has served as general partner and managing director of CID Capital, a venture capital firm he joined after previously serving as president and chief exectuive officer of The Fuller Brush Company, a supplier of consumer products. Dr. Aplin holds a B.S. in business administration from Drake University, and an M.A. in industrial and labor relations and a Ph.D. in business administration from the University of Iowa. Dr. Aplin is also a certified management consultant.

Douglas G. Bailey

Douglas G. Bailey has served as a member of our board of directors since July 2001. Mr. Bailey is the founder of American Bailey Corporation (ABC), a private equity firm for which he has served as president since 1984 and as chief executive officer since 1996. Mr. Bailey has served as the president and chief executive officer since April 2010, chairman of the board of directors since January 2010, deputy chairman from 2002 through 2009, and a director since April 1998 of Fuel-Tech, a fuel technology company. Mr. Bailey holds a B.S., an M.S. and an Engineer's degree, all in mechanical engineering from Massachusetts Institute of Technology, and an M.B.A. from Harvard Business School.

Fred A. Middleton
Fred A. Middleton has served as a member of our board of directors since July 2001. Since 1987, Mr. Middleton has been a general partner and managing director of Sanderling Ventures, a biomedical venture capital firm. During the last 20 years, Mr. Middleton has served in a number of management roles and as a member of the board of directors for over 20 biomedical companies. Mr. Middleton currently serves as chairman of the board of directors of Stereotaxis, a medical device company, and as a member of the board of directors of CardioNet, a cardiac rhythm services company. Mr. Middleton also serves on the board of directors of five other privately-held biomedical and biotechnology companies. Mr. Middleton holds a BS in chemistry from the Massachusetts Institute of Technology and an MBA with distinction from Harvard Business School.

Ann F. Hanham Ph.D.
Ann F. Hanham, Ph.D. has served as a member of our board of directors since November 2004. Dr. Hanham joined Burrill & Company, a venture capital and merchant banking firm, in February 2000 and has served as a managing director there since January 2002. Dr. Hanham served on the board of directors of BioMimetic Therapeutics, Inc., a biopharmaceutical company, from May 2001 to September 2006; Biotie Therapies, a drug discovery and development company, from March 2009 to April 2010; and Targacept, a biopharmaceutical company, from September 2005 to August 2006. Dr. Hanham holds a B.Sc. from the University of Toronto, a M.Sc. from Simon Fraser University and a Ph.D. from the University of British Columbia.

Keith E. Brauer
Keith E. Brauer has served as a member of our board of directors since 2006. From 1988 to 1994, Mr. Brauer served in various executive roles at Eli Lilly and Company, a healthcare company, and most recently as executive director and chief accounting officer. From July 1994 to April 2006, Mr. Brauer served as vice president, finance and chief financial officer of Guidant, which was acquired by Boston Scientific Corporation, a medical device company, in April 2006. Mr. Brauer holds a B.S. in management from Indiana University and an M.B.A. from the University of Michigan.

Peter D. Meldrum Ph.D.

Dr. Meldrum is currently the President and Chief Executive Officer of Myriad Genetics, a position he has held since 1992.  Prior to his time at Myriad, he was President and Chief Executive Officer of Founders Fund, Inc., a venture capital group investing in the biotechnology industry and has been active in the biotechnology industry for over 35 years. Mr. Meldrum received a B.S. in chemical engineering, a M.B.A., a Ph.D. in engineering (honorary) from the University of Utah, and, a Ph.D. in science  (honorary) from Westminster College. 

Marc Kozin

Mr. Kozin is currently a Senior Advisor to L.E.K. Consulting, a global strategy consulting firm. Having served as president of L.E.K.’s North American practice for 15 years, Mr. Kozin has nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally.  He also has deep industry expertise advising biopharmaceutical, life sciences, and medical technology companies. Mr. Kozin also serves on the boards of UFP Technologies, Medical Simulation Corporation, Crunchtime Information Systems and DukeEngage. Mr. Kozin received his B.A. with distinction, Magna Cum Laude, in Economics from Duke University. He was also awarded an M.B.A. with distinction from The Wharton School, University of Pennsylvania.

Lesley Russell M.B.Ch.B, MRCP
Dr. Russell served as senior vice president and head of research and development for global branded products at Teva Pharmaceuticals until June 2012. Prior to this she was executive vice president and chief medical officer at Cephalon. Dr. Russell joined Cephalon in 2000 and held various positions of increasing responsibility, including head of clinical research and medical affairs, prior to becoming Cephalon’s chief medical officer in September 2006. During her tenure at Cephalon, Dr. Russell filed multiple NDAs to the FDA and marketing authorization applications (MAAs) to the Committee for Medicinal Products for Human Use (CHMP). Before joining Cephalon, Dr. Russell held positions of increasing responsibility at Amgen U.K., Lilly Industries, U.K., and U.S. Bioscience, now acquired by MedImmune Oncology. Dr. Russell received a M.B.Ch.B. degree from the University of Edinburgh, Scotland. She is a member of the Royal College of Physicians, U.K., and is registered with the General Medical Council, U.K. She currently serves as a member of the board of directors of AMAG Pharma, a company traded on NASDAQ.